[Asia Economy Reporter Minwoo Lee] Korea Asset Investment Securities' stock price is on the rise. The expectation of introducing Russia's COVID-19 vaccine 'Sputnik V' has increased, highlighting news that the company holds shares in a consortium involved in the subcontracted production of the vaccine.
At 1:54 PM on the 22nd, Korea Asset Investment Securities' stock price recorded 115,000 KRW, up 10.58% from the previous day. This appears to be influenced by President Moon Jae-in's directive to review the introduction of vaccines with confirmed safety in addition to existing vaccines, bringing attention to the Russian vaccine. It is reported that Blue House aides recently suggested the need to consider the introduction of the Sputnik V vaccine developed by Russia. Son Young-rae, head of the Social Strategy Division at the Central Disaster and Safety Countermeasures Headquarters (CDSCH), also stated at a press briefing that "We are closely monitoring the approval trends of new vaccines," and "The approval authority (Ministry of Food and Drug Safety) is analyzing a large amount of information to make a comprehensive judgment."
Earlier, at the end of February, Korea Chorus, a subsidiary of GL Rapha, signed a memorandum of understanding (MOU) with seven organizations including Binex, Boryung Biopharma, Isu Abxis, Chong Kun Dang Bio, Curatis, Humedix, and Andong Animal Cell Validation Support Center to form a consortium for subcontracted production of Sputnik V. Korea Asset Investment Securities holds 1,860,440 shares (8.58%) of Curatis through the ‘KAI-Yeollim Healthcare Investment Fund’.
Meanwhile, at the same time, the stock prices of Isu Abxis (18.32%) and Humedix (1.42%) are also on the rise.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
